Disc Medicine公司在2026年美国临床肿瘤学会年会上，公布了其Rally-Mf二期临床试验的最新积极数据。这项研究专门针对伴有贫血的骨髓纤维化患者，结果显示，试验药物BIT-1在改善患者贫血症状和脾脏体积方面表现出持续的疗效和良好的耐受性。这些更新的数据进一步支持了BIT-1作为一种潜在创新疗法的前景，为目前治疗选择有限的患者群体带来了新的希望。公司计划基于这些积极结果，与监管机构进行沟通，以推进后续的临床开发。
Disc Medicine公司在2026年美国临床肿瘤学会年会上，公布了其Rally-Mf二期临床试验的最新积极数据。这项研究专门针对伴有贫血的骨髓纤维化患者，结果显示，试验药物BIT-1在改善患者贫血症状和脾脏体积方面表现出持续的疗效和良好的耐受性。这些更新的数据进一步支持了BIT-1作为一种潜在创新疗法的前景，为目前治疗选择有限的患者群体带来了新的希望。公司计划基于这些积极结果，与监管机构进行沟通，以推进后续的临床开发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.